Abstract
The prevalence of Alzheimer’s disease is rapidly increasing, with an expected growth to 152.8 million cases globally in 2050. A common concern for patients and caregivers is how much time remains until progression to severe stages of dementia. Moreover, predicting time by disease stage can be beneficial for clinical decision making and policy decisions around the value and use of disease-modifying therapies (DMT). We aim to determine the sojourn time by stages of disease severity and care setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
